Clinical Trials

UVA Health System frequently opens new clinical trials, offering your patients the latest investigational treatments.

For a complete list of active cancer trials and study coordinator contact information, visit our newly launched Find a Clinical Trial website. If you have patients who may be eligible to participate in a cancer clinical trial, please email cancerclinicaltrials@virginia.edu.

 

 

 

New Trials Available at UVA

Genitourinary Oncology (IRB-HSR #21599)

Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC) (NCT03055013)

Primary Investigator: Robert Dreicer

Clinical Research Coordinator: Jennifer Drake

Gynecologic Oncology (IRB-HSR #21714)

A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors (NCT03861403)

Primary Investigator: Linda Duska

Clinical Research Coordinator: Anne Gabel

Hematologic Malignancies (IRB-HSR #21391)

A Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination with High Dose Cytarabine and Mitoxantrone (CHAM) Compared to High Dose Cytarabine and Mitoxantrone (HAM) in Older Patients (60 years) with Relapsed/Refractory Acute Myeloid Leukemia (AML) (NCT03504410)

Primary Invstigator: Michael Keng

Clinical Research Coordinator: Karen Johnson, Kim Underwood

Advanced Solid Tumors (IRB-HSR #21503)

A Phase I, First-in-Human, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 Administered Daily for 28 Days to Patients with Advanced Solid Tumors (NCT03715504)

Primary Investigator: Patrick Dillon

Clinical Research Coordinator: Stephen Hazen

Thoracic Oncology (IRB-HSR #21757)

A phase II study of Carboplatin plus Pemetrexed plus Atezolizumab plus Bevacizumab in chemotherapy and immunotherapy-naïve patients with stage IV non-squamous, non-small cell lung cancer: Big Ten Cancer Research Consortium BTCRC-LUN17-139 (NCT03713944)

Primary Investigator: Ryan Gentzler

Clinical Research Coordinator: Gracie Hockenberry

Gynecologic Oncology (IRB-HSR #21532)

A Phase II Trial of Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium (NCT03476798)

Primary Investigator: Leigh Cantrell

Clinical Research Coordinator: Sheena Clift

Squamous Cell Carcinoma (IRB-HSR #21217)

A Pivotal, Double-Blind, Randomized, Placebo-Controlled, Multinational Study of SGX942 (Dusquetide) for the Treatment of Oral Mucositis in Patients Being Treated with Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck (NCT03237325)

Primary Investigator: Varinder Kaur

Clinical Research Coordinator: Olusegun Adelaia

Solid Tumors, Head & Neck (IRB-HSR #21552)

Tazemetostat Expanded Access Program for Adults with Solid Tumors (NCT03874455)

Primary Investigator: Elizabeth Gaughan

Clinical Research Coordinator: Emily Allred

Cryptogenic Stroke (IRB-HSR #20547)

ARCADIA: AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke (NCT03192215)

Primary Investigator: Andrew Southerland

Clinical Research Coordinator: Sonya Gunter

 

Ovarian Cancer (IRB-HSR#21535)

Open Label Phase 2 Study of Tisotumab Vedotin for Patients with Platinum-Resistant Ovarian Cancer with a Safety Run-in of a Dose-Dense Regimen (NCT03657043)

Primary Investigator: Linda Duska

Clinical Research Coordinator: Anne Gabel

Ovarian Cancer (IRB-HSR ##21561)

A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometroid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometroid (NCT03348631)

Primary Investigator: Linda Duska

Clinical Research Coordinator: Anne Gabel